Menditto Enrica, Orlando Valentina, Coretti Silvia, Putignano Daria, Fiorentino Denise, Ruggeri Matteo
CIRFF, Center of Pharmacoeconomics, Federico II University of Naples, Naples, Italy.
Postgraduate School of Health Economics and Management (ALTEMS), Università Cattolica del Sacro Cuore, School of Economics, Rome, Italy.
Clinicoecon Outcomes Res. 2015 Nov 11;7:575-81. doi: 10.2147/CEOR.S88531. eCollection 2015.
Agency is a pervasive feature of the health care market, with doctors acting as agents for both patients and the health care system. In a context of scarce resources, doctors are required to take opportunity cost into account when prescribing treatments, while cost containment policies cannot overlook their active role in determining health care resource allocation. This paper addresses this issue, investigating the effects of cost containment measures in the market of biosimilar drugs that represent a viable and cost-saving strategy for the reduction of health care expenditure. The analysis focuses on a particular region in Italy, where several timely policies to incentivize biosimilar prescribing were launched.
Drugs were identified by the anatomical therapeutic chemical classification system. Information about biosimilar drugs and their originator biological products was extracted from the IMS Health regional database. Drug consumption was expressed in terms of counting units, while expenditure was evaluated in Euro (€). The market penetration of biosimilars was analyzed by year and quarterly.
In the Campania region of Italy, the effects of cost containment policies, launched between 2009 and 2013, showed the prescription of biosimilars strongly increasing in 2010 until prescribing levels reached and exceeded the market share of the reference biological products in 2012. After a slight reduction, a plateau was observed at the beginning of 2013. At the same time, the use of the originator products had been decreasing until the first quarter of 2011. However, after a 1-year plateau, this trend was reversed, with a new increase in the consumption of the originators observed.
Results show that the cost containment policies, applied to cut health expenditure "to cure and not to care", did not produce the cultural change necessary to make these policies effective in the long run. Therefore, top-down policies for cost containment are not successful; rather, a bottom-up approach based on consensus among professionals should become the preferred option.
代理关系是医疗保健市场的一个普遍特征,医生充当患者和医疗保健系统双方的代理人。在资源稀缺的情况下,医生在开处方时需要考虑机会成本,而成本控制政策不能忽视他们在决定医疗保健资源分配方面的积极作用。本文探讨了这一问题,研究了成本控制措施对生物类似药市场的影响,生物类似药是一种可行的、节省成本的策略,有助于降低医疗保健支出。分析聚焦于意大利的一个特定地区,该地区出台了多项及时的政策来激励生物类似药的处方开具。
通过解剖治疗化学分类系统识别药物。从艾美仕市场研究公司(IMS Health)的区域数据库中提取有关生物类似药及其原研生物制品的信息。药物消费以计数单位表示,而支出则以欧元(€)评估。按年份和季度分析生物类似药的市场渗透率。
在意大利坎帕尼亚地区,2009年至2013年期间实施的成本控制政策的效果显示,生物类似药的处方量在2010年强劲增长,直至2012年处方水平达到并超过了参比生物制品的市场份额。在略有下降之后,2013年初出现了一个平稳期。与此同时,原研产品的使用量一直在下降,直到2011年第一季度。然而,在经历了1年的平稳期后,这一趋势发生了逆转,原研产品的消费量出现了新的增长。
结果表明,旨在削减医疗支出“治病而非关怀”的成本控制政策,并未产生使这些政策长期有效的文化变革。因此,自上而下的成本控制政策并不成功;相反,基于专业人士共识的自下而上的方法应成为首选方案。